JP2008505143A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008505143A5 JP2008505143A5 JP2007519679A JP2007519679A JP2008505143A5 JP 2008505143 A5 JP2008505143 A5 JP 2008505143A5 JP 2007519679 A JP2007519679 A JP 2007519679A JP 2007519679 A JP2007519679 A JP 2007519679A JP 2008505143 A5 JP2008505143 A5 JP 2008505143A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- kit according
- antibody
- antigen
- weeks
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 19
- 206010028980 Neoplasm Diseases 0.000 claims 12
- 239000000427 antigen Substances 0.000 claims 11
- 102000036639 antigens Human genes 0.000 claims 11
- 108091007433 antigens Proteins 0.000 claims 11
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 claims 10
- 101100165850 Homo sapiens CA9 gene Proteins 0.000 claims 10
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 7
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 7
- 238000002271 resection Methods 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 3
- 210000001165 lymph node Anatomy 0.000 claims 3
- 206010009253 Clear cell sarcoma of the kidney Diseases 0.000 claims 2
- 208000030748 clear cell sarcoma of kidney Diseases 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 101100282617 Bovine herpesvirus 1.1 (strain Cooper) gC gene Proteins 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 208000007660 Residual Neoplasm Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 238000009098 adjuvant therapy Methods 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 210000004408 hybridoma Anatomy 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 230000000683 nonmetastatic effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58467904P | 2004-07-02 | 2004-07-02 | |
| PCT/EP2005/006994 WO2006002889A2 (en) | 2004-07-02 | 2005-06-29 | Improved adjuvant therapy of g250-expressing tumors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008505143A JP2008505143A (ja) | 2008-02-21 |
| JP2008505143A5 true JP2008505143A5 (enExample) | 2008-05-29 |
Family
ID=35431139
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007519679A Pending JP2008505143A (ja) | 2004-07-02 | 2005-06-29 | Ｇ２５０発現腫瘍の改善されたアジュバント療法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7691375B2 (enExample) |
| EP (2) | EP2497497B1 (enExample) |
| JP (1) | JP2008505143A (enExample) |
| KR (1) | KR101205289B1 (enExample) |
| CN (1) | CN101052416B (enExample) |
| AU (1) | AU2005259481B2 (enExample) |
| BR (1) | BRPI0512854A (enExample) |
| CA (1) | CA2566950A1 (enExample) |
| DK (1) | DK2497497T3 (enExample) |
| ES (1) | ES2641089T3 (enExample) |
| MX (1) | MXPA06013240A (enExample) |
| RU (2) | RU2371198C2 (enExample) |
| WO (1) | WO2006002889A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040077081A1 (en) * | 2001-02-07 | 2004-04-22 | Egbert Oosterwijk | Hybridoma cell line g250 and its use for producing monoclonal antibodies |
| US20090162382A1 (en) * | 2002-03-01 | 2009-06-25 | Bernett Matthew J | Optimized ca9 antibodies and methods of using the same |
| EP1524995B1 (en) * | 2002-07-01 | 2011-12-21 | Wilex AG | Co-administration of cg250 and il-2 or ifn-alpha for treating cancer such as renal cell carcinomas |
| CN102576025A (zh) | 2009-09-18 | 2012-07-11 | 三菱化学株式会社 | 肝细胞癌标记物 |
| RU2442983C1 (ru) * | 2011-01-14 | 2012-02-20 | Государственное учреждение здравоохранения Научно-исследовательский институт скорой помощи имени Н.В. Склифосовского Департамента здравоохранения г. Москвы | Способ прогнозирования безрецидивной выживаемости по молекулярным факторам у больных с метастазами колоректального рака в печени после ее резекции |
| AU2013328580B2 (en) | 2012-10-12 | 2016-01-21 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| MX363845B (es) | 2013-02-22 | 2019-04-05 | Wilex Ag | Anticuerpo anti-caix para usarse en el tratamiento de carcinoma de células claras renales. |
| MX362970B (es) | 2013-03-13 | 2019-02-28 | Medimmune Ltd | Pirrolobenzodiazepinas y conjugados de las mismas. |
| CN106687141A (zh) | 2014-09-10 | 2017-05-17 | 麦迪穆有限责任公司 | 吡咯并苯并二氮杂卓及其缀合物 |
| WO2018069289A1 (en) | 2016-10-11 | 2018-04-19 | Medimmune Limited | Antibody-drug conjugates with immune-mediated therapy agents |
| SG11202010469QA (en) | 2018-05-23 | 2020-11-27 | Adc Therapeutics Sa | Molecular adjuvant |
| WO2022079211A1 (en) | 2020-10-16 | 2022-04-21 | Adc Therapeutics Sa | Glycoconjugates |
| GB202102396D0 (en) | 2021-02-19 | 2021-04-07 | Adc Therapeutics Sa | Molecular adjuvant |
| EP4426727A2 (en) | 2021-11-03 | 2024-09-11 | Hangzhou Dac Biotech Co., Ltd. | Specific conjugation of an antibody |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1988008854A1 (en) | 1987-05-06 | 1988-11-17 | Egbert Oosterwijk | Monoclonal antibodies to renal cell carcinoma |
| US5387676A (en) * | 1992-03-11 | 1995-02-07 | Ciba Corning Diagnostics Corp. | MN gene and protein |
| US6417337B1 (en) * | 1996-10-31 | 2002-07-09 | The Dow Chemical Company | High affinity humanized anti-CEA monoclonal antibodies |
| EP1385959A2 (en) | 2001-02-07 | 2004-02-04 | Wilex AG | Method of producing recombinant antibodies against tumours |
| ATE444308T1 (de) * | 2002-02-13 | 2009-10-15 | Ludwig Inst Cancer Res | Fusionsproteine humanisierter g250-spezifischer antikörper sowie verwendungen davon |
| EP1524995B1 (en) | 2002-07-01 | 2011-12-21 | Wilex AG | Co-administration of cg250 and il-2 or ifn-alpha for treating cancer such as renal cell carcinomas |
| RU2257200C1 (ru) * | 2004-05-12 | 2005-07-27 | Кутушов Михаил Владимирович | Лекарственное средство |
-
2005
- 2005-06-29 BR BRPI0512854-4A patent/BRPI0512854A/pt not_active Application Discontinuation
- 2005-06-29 ES ES12171081.8T patent/ES2641089T3/es not_active Expired - Lifetime
- 2005-06-29 CN CN2005800205034A patent/CN101052416B/zh not_active Expired - Fee Related
- 2005-06-29 EP EP12171081.8A patent/EP2497497B1/en not_active Expired - Lifetime
- 2005-06-29 WO PCT/EP2005/006994 patent/WO2006002889A2/en not_active Ceased
- 2005-06-29 KR KR1020067027704A patent/KR101205289B1/ko not_active Expired - Fee Related
- 2005-06-29 AU AU2005259481A patent/AU2005259481B2/en not_active Expired
- 2005-06-29 MX MXPA06013240A patent/MXPA06013240A/es active IP Right Grant
- 2005-06-29 JP JP2007519679A patent/JP2008505143A/ja active Pending
- 2005-06-29 RU RU2007104040/14A patent/RU2371198C2/ru not_active IP Right Cessation
- 2005-06-29 US US11/630,170 patent/US7691375B2/en active Active
- 2005-06-29 DK DK12171081.8T patent/DK2497497T3/en active
- 2005-06-29 CA CA002566950A patent/CA2566950A1/en not_active Abandoned
- 2005-06-29 EP EP05775970A patent/EP1763367A2/en not_active Ceased
-
2009
- 2009-06-10 RU RU2009122344/15A patent/RU2519340C2/ru not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2009122344A (ru) | Улучшенная вспомогательная терапия опухолей, экспрессирующих g250 | |
| JP2008505143A5 (enExample) | ||
| JP6359492B2 (ja) | 抗ＩＬ−１α抗体による癌の処置方法 | |
| TW201808330A (zh) | 藉由投予ｐｄ－１抑制劑治療皮膚癌之方法 | |
| TW202005981A (zh) | 高親和性、異構體選擇性之TGFβ1抑制劑及其用途 | |
| RU2017127772A (ru) | Человеческие антитела к токсинам clostridium difficile | |
| JP2015509962A5 (enExample) | ||
| JP2011006464A (ja) | 喘息の治療における抗−ＴＮＦα抗体 | |
| JP2020522280A5 (enExample) | ||
| JP2020522281A5 (enExample) | ||
| JP2020533965A5 (enExample) | ||
| JP2018512402A5 (enExample) | ||
| JP2020531003A5 (enExample) | ||
| WO2023061472A1 (zh) | 抗her2抗体药物偶联物和酪氨酸激酶抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| EP4541423A2 (en) | Dosing regimen of avelumab for the treatment of cancer | |
| CN117427186A (zh) | 抗her2抗体药物偶联物联合抗pd-l1抗体在制备治疗肺癌的药物中的用途 | |
| US20240009275A1 (en) | Combination immunotherapy of il-15 and cd40 agonist in cancer treatment | |
| TWI619728B (zh) | Ｇｉｓｔ之治療 | |
| CN119677533A (zh) | 用于治疗癌症的检查点抑制剂与溶瘤病毒的组合 | |
| JP2022044827A (ja) | 免疫媒介性がん治療のための組成物及び方法 | |
| US11623003B2 (en) | Vaccination against diabetes, obesity and complications thereof | |
| JP7756452B2 (ja) | 肺、腎臓、または肝臓の線維症疾患の処置に使用するためのｐｓｍｐアンタゴニスト | |
| US20230338496A1 (en) | Vaccination against diabetes, obesity and complications thereof | |
| EP3389704B1 (en) | Vaccination against diabetes, obesity and complications thereof | |
| JP2020517648A5 (enExample) |